Results 301 to 310 of about 216,666 (331)
Some of the next articles are maybe not open access.
Current Opinion in Internal Medicine, 2006
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Christopher J, Hawkey, Paul J, Fortun
+5 more sources
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Christopher J, Hawkey, Paul J, Fortun
+5 more sources
2001
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
A S, Nies, M J, Gresser
openaire +2 more sources
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
A S, Nies, M J, Gresser
openaire +2 more sources
Cyclooxygenase-2 and carcinogenesis
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2000Numerous investigations have shown that COX-2 is a participant in the pathway of colon carcinogenesis, especially when mutation of the APC tumor suppressor is the initiating event. Moreover, it seems that the amount of COX-2 is important, since there is a correlation between its level of expression and the size of the tumors and their propensity to ...
S M, Prescott, F A, Fitzpatrick
openaire +2 more sources
Cyclooxygenase-2 and atherosclerosis
Current Opinion in Lipidology, 2002Cyclooxygenase regulates the production of eicosanoids, which modulate physiologic processes in the vessel wall contributing to atherosclerosis and thrombosis, including platelet aggregation, control of vascular tone, and the local inflammatory response.
MacRae F, Linton, Sergio, Fazio
openaire +2 more sources
Annual Review of Pharmacology and Toxicology, 1998
▪ Abstract Cyclooxygenase (COX), first purified in 1976 and cloned in 1988, is the key enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid. In 1991, several laboratories identified a product from a second gene with COX activity and called it COX-2.
J R, Vane, Y S, Bakhle, R M, Botting
openaire +2 more sources
▪ Abstract Cyclooxygenase (COX), first purified in 1976 and cloned in 1988, is the key enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid. In 1991, several laboratories identified a product from a second gene with COX activity and called it COX-2.
J R, Vane, Y S, Bakhle, R M, Botting
openaire +2 more sources
Current Pharmaceutical Design, 2003
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A(2) and the release of arachidonic acid from membrane phospholipids in response to the interaction of a stimulus with a receptor on the cell surface. Arachidonic acid is subsequently transformed by the enzyme cyclooxygenase (COX) to prostaglandins (PGs)
openaire +2 more sources
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A(2) and the release of arachidonic acid from membrane phospholipids in response to the interaction of a stimulus with a receptor on the cell surface. Arachidonic acid is subsequently transformed by the enzyme cyclooxygenase (COX) to prostaglandins (PGs)
openaire +2 more sources
Cyclooxygenase-2 Inhibition and Coagulation
Journal of Cardiovascular Pharmacology, 2006Selective inhibitors of cyclooxygenase-2 (COX-2) have come under scrutiny because of a possibly increased thrombotic risk observed in retrospective studies and comparatively small cancer trials. Indeed, inhibition of COX-2 may favor a prothrombotic environment by suppressing endothelial prostacyclin synthesis while leaving COX-1-dependent platelet ...
Steffel, J +3 more
openaire +3 more sources
Cyclooxygenase-2 selective inhibitors
Drugs of Today, 1999The identification of two cyclooxygenase (COX) enzymes has been a tremendous advance in understanding the role of prostaglandins in inflammation and the actions of nonsteroidal antiinflammatory drugs (NSAIDs). COX-1 activity appears to be related to "constitutive" or "housekeeping" functions in the gastric mucosa, kidney and platelets.
openaire +2 more sources
Cyclooxygenase-2 in oncogenesis
Clinica Chimica Acta, 2011Compelling experimental and clinical evidence supports the notion that cyclooxygenase-2, the inducible isoform of cyclooxygenase, plays a crucial role in oncogenesis. Clinical and epidemiological data indicate that aberrant regulation of cyclooxygenase-2 in certain solid tumors and hematological malignancies is associated with adverse clinical outcome.
openaire +2 more sources
Clinical Cancer Research, 2004
Abstract Purpose: Recent studies have shown that cyclooxygenase (Cox)-2 may be involved in colorectal carcinogenesis. We aimed to determine whether Cox-2 expression in itself can predict outcome of colorectal cancer patient after surgery. In addition, the expression of Cox-1 was also evaluated.
Labile Togba Soumaoro +5 more
openaire +1 more source
Abstract Purpose: Recent studies have shown that cyclooxygenase (Cox)-2 may be involved in colorectal carcinogenesis. We aimed to determine whether Cox-2 expression in itself can predict outcome of colorectal cancer patient after surgery. In addition, the expression of Cox-1 was also evaluated.
Labile Togba Soumaoro +5 more
openaire +1 more source